Navigation Links
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
Date:7/13/2009

ROCKVILLE, Md., July 13 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system infection due to West Nile Virus (WNV). MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, was awarded a $50 million contract in September 2006 from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to support the development of MGAWN1.

The PARADIGM trial is a randomized, double-blind, multicenter, placebo-controlled study that is designed to evaluate the safety and efficacy of MGAWN1 in patients greater than or equal to 18 years of age with signs and symptoms of acute West Nile Neuroinvasive Disease. Approximately 20 sites in North America will be utilized for the conduct of the PARADIGM trial. For more information on the PARADIGM trial, please see www.clinicaltrials.gov.

MacroGenics also announced today the completion ofa Phase 1 study of MGAWN1 in healthy volunteers, with the last patient having completed treatment in late 2008. This randomized, double-blind, dose-escalation cohort study was designed to evaluate the safety, tolerability, and pharmacokinetics of a single infusion of MGAWN1 in healthy adults. The study demonstrated the drug to be safe and well tolerated at all doses tested.

"We are delighted with the initiation of the PARADIGM trial as well as the completion of the Phase 1 trial," stated Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Currently, there are no approved treatments for individuals with severe West Nile Virus infection. These patients are hospitalized and receive
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Paulo F. Costa Joins MacroGenics Board of Directors
2. MacroGenics Appoints New Vice President of Business Development
3. MacroGenics Raises $25M in Series D-2 Financing
4. MacroGenics Acquires Raven Biotechnologies
5. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... ME (PRWEB) December 18, 2014 Ed ... director of the Center for Excellence in the Neurosciences ... New England, has been selected as a member of ... is the first neuroscientist from Maine to receive this ... nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 “Never ... at Philipps- Universität Marburg’s Department of Physics, advises ... in the newly released SPIE Women in ... be too shy to ask questions.” , In ... engineering, and mathematics) occupations ranging from university professor ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... Exelixis,Inc. (Nasdaq: EXEL ) announced earlier today ... Deerfield Management. The arrangement will,be discussed by Exelixis management ... ET today, Thursday, June 5. To listen to a ... Investors at, http://www.exelixis.com ., A replay of the ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced that ... B Decoy (NF-kB Decoy) program, which includes the,clinical ... NF-kB Transcription Factor Decoy inhibits NF-kappa B, a ... as inflammatory,bowel disease (IBD), eczema, rheumatoid arthritis, and ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Annual Global Healthcare Conference on Tuesday,June 10, at ... a live,webcast of the presentation on our website ... recommended that listeners log on 15 minutes early ...
Cached Biology Technology:Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 2Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 3
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... next generation of treatments for shock or stroke could be ... ?neuroglobin. In a review article to be published in the ... Rome describe this protein, which may be the key to ... for patients. , The Italian researchers suggest that neuroglobin is ...
... be used to return severely failing hearts to their ... according to new research. , The mechanical devices, known ... in patients with very severe heart failure whilst they ... England Journal of Medicine, shows that using an LVAD ...
... will fund a 5-year study examining why dead zones have ... allow them to detect the cause and stop the spread ... is a very serious problem," said University of Michigan's Donald ... and lead investigator of the project. "In the 1960s and ...
Cached Biology News:Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal 2Researchers to study why dead zone returned to Lake Erie 2
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
anti-achaete...
... Super-Sensitive, Super-Dark, Super-Small! ... with the ChemiDoc-It Imaging System. High-sensitivity ... produces low-background noise and wide dynamic ... a short exposure time. The light-tight ...
... Based Oligonucleotide) Genome Set and MEEBO (Mouse ... contain a collection of open source oligo ... allowing interrogation of thousands of genes. Developed ... University and UCSF, the sets enable the ...
Biology Products: